Ensign Peak Advisors
CUE icon

Ensign Peak Advisors’s Cue Biopharma CUE Stock Holding History

Ensign Peak Advisors’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-599
Closed -$45K – 2316
2022
Q2 		$45K Buy
599
+252
+73% +$29.5K ﹤0.01% 2071
2022
Q1 		$51K Hold
347
– – ﹤0.01% 2128
2021
Q4 		$118K Buy
+347
New +$134K ﹤0.01% 2038

Other funds holding CUE

PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ensign Peak Advisors's CUE Position: Q3 2022 in Review

Ensign Peak Advisors sold out of Cue Biopharma (CUE) in Q3 2022, closing a stake of 599 shares — an estimated $45K sold.

Ensign Peak Advisors first reported a position in CUE in Q4 2021 and held it in 3 quarters. The position peaked at $118K in Q4 2021. 64 funds tracked by Wall St. Rank hold CUE as of Q3 2022.

  • Ensign Peak Advisors reported no remaining Cue Biopharma position as of Q3 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 599 Cue Biopharma shares in Q3 2022, an estimated $45K.
  • Ensign Peak Advisors first reported a position in Cue Biopharma in Q4 2021 and held it in 3 quarters.
  • Ensign Peak Advisors's Cue Biopharma position peaked at $118K in Q4 2021.
  • 64 funds tracked by Wall St. Rank held Cue Biopharma as of Q3 2022.

Based on Ensign Peak Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.